Results 111 to 120 of about 2,108 (191)

Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease? [PDF]

, 2022
Chia, Mark A, Keane, Pearse A
core  

Switching to Faricimab for Polypoidal Choroidal Vasculopathy with Real-World Outcomes in Refractory Cases – The FAR-PEARL Study Report 1

Clinical Ophthalmology
Kenneth CS Fong,1 Wilson Jun Jie Wong,1 Hon Seng Wong,1 Kiet Phang Ling,1 Shir-Ning Fong,2 Manoharan Shunmugam1 1OasisEye Specialists, Kuala Lumpur, Kuala Lumpur, Malaysia; 2University of Nottingham Medical School, Nottingham, NG72UH, UKCorrespondence ...
Fong KC, Wong WJJ, Wong HS, Ling KP, Fong SN, Shunmugam M   +5 more
doaj  

Twelve-month lesion reactivation after initial loading injections of faricimab in neovascular AMD: a comparison between three and four loading injections. [PDF]

BMC Ophthalmol
Han HY, Park SM, Lee JH, Kim CG, Kim JH.
europepmc   +1 more source

Emerging drugs for the treatment of diabetic retinopathy [PDF]

, 2020
Caccioppo, Andrea, Castellino, Niccolò, Porta, Massimo, Reibaldi, Michele, Striglia, Elio   +4 more
core   +1 more source

Short-Term Outcomes of 3 Monthly intravitreal Faricimab On Different Subtypes of Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Asako Tanaka, Masayuki Hata, Memiri Tsuchikawa, Naoko Ueda-Arakawa Ueda-Arakawa, Hiroshi Tamura, Manabu Miyata, Ayako Takahashi, Ai Kido, Yuki Muraoka, Masahiro Miyake, Sotaro Ooto, Akitaka Tsujikawa Department of Ophthalmology and Visual Sciences, Kyoto
Tanaka A, Hata M, Tsuchikawa M, Ueda-Arakawa NUA, Tamura H, Miyata M, Takahashi A, Kido A, Muraoka Y, Miyake M, Ooto S, Tsujikawa A   +11 more
doaj  

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration [PDF]

\ua9 The Author(s) 2024.Introduction: Neovascular age-related macular degeneration is a global public-health concern, associated with a considerable burden to individuals, healthcare systems, and society.
Amoaku WM, Aslam T, Barratt J, Cheung CMG, Eldem B, Finger RP, Gale RP, Kodjikian L, Koh A, Korobelnik J-F, Lin X, Loewenstein A, Mitchell P, Murphy M, Okada M, Pearce I, Rodriguez FJ, Stern J, Sylvanowicz M, Talks SJ, Wong DT, Wong TY, Ziemssen F   +22 more
core  

Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration

Clinical Ophthalmology
Berenike Cornelia Kunzmann, Alexandra Stefanie Schweig, Karl Ulrich Bartz-Schmidt, Bianka Sobolewska University Eye Hospital, Centre for Ophthalmology, University of Tuebingen, Tuebingen, GermanyCorrespondence: Berenike Cornelia Kunzmann, University Eye ...
Kunzmann BC, Schweig AS, Bartz-Schmidt KU, Sobolewska B   +3 more
doaj  

Early Latin American experience with faricimab for retinal diseases: FARI-LATAM study for the Pan-American collaborative retina study (PACORES) group. [PDF]

Int J Retina Vitreous
Wu L, Rojas S, Rao X, Politis M, Roca JA, Nehemy M, Berrocal MH, Fromow-Guerra J, Barraza-Lino K, Lopez C, Maia M, Cardenas-Mirón A, Gabela G, Baldivieso-Hurtado O, Gabela C, Chinchilla L, Verdaguer JI, Zas M, Young M, García-Aguirre G, Ramirez-Estudillo JA, Abreu N, Flores M, Velez W, Baez Y, Arriola-Lopez A, Casella AM.   +26 more
europepmc   +1 more source

Transient vitreous opacity following combined intravitreal injection of pegcetacoplan and faricimab-svoa in patients with neovascular age-related macular degeneration and geographic atrophy. [PDF]

Am J Ophthalmol Case Rep
Zhang Y, Wei C, Stewart JM.
europepmc   +1 more source

Anti-VEGF Therapies in Retinal Disorders: Current Landscape and Future Directions. [PDF]

Clin Ophthalmol
Sheth JU.
europepmc   +1 more source